- Next-week expectancy is positive at 55.10% based on similar historical setup states.
VNDA
NASDAQ
Week ended 07 Aug 2026
Weekly Investor Report
Vanda Pharmaceuticals Inc · Healthcare · Biotechnology
Latest close
5.00 USD
-2.0%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -24.8% below the Trend Line and sits at 14.7% of its 52-week range. The latest completed week returned -2.0%, after a -19.9% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 42/100 conviction, while the latest news-sentiment score is 53/100.
Setup score
30
out of 100
Latest Close
5.00 USD
7 Aug 2026
1W Return
-2.0%
latest completed week
4W Return
-19.9%
short-term follow-through
12W Return
-20.4%
quarterly tape
Trend Breadth
65.4%
34 of 52 weeks active
Volume Ratio
1.5x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-2.0%
Latest completed week; four-week move -19.9%.
Indicator stack
36/27
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Positive 55.10%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Bullish
42/100 conviction; expected move 14.0%.
News sentiment
53/100
64 relevant articles in the latest sentiment read.
Event risk
05 Aug
Latest stored earnings date was 05 Aug 2026.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -24.8% below the Trend Line and sits at 14.7% of its 52-week range. The latest completed week returned -2.0%, after a -19.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.5x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0612-week average 0.26
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.06Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -19.9% over four weeks, -20.4% over 12 weeks, and 19.0% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year34
Trend breadth65.4%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.25Latest activity-pressure read.
Pressure change-10.7%Four-week change in activity pressure.
Leadership-28.59Latest relative-leadership reading.
RS change-147.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 30 Jun 2026
Field coverage 82%
Model confidence 82%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength20/100Blend of value, momentum, and quality. Underlying universe rank 81; rank 1 is best.
Value34/100Relative valuation strength. Underlying universe rank 67; rank 1 is best.
Quality9/100Profitability and accounting quality. Underlying universe rank 92; rank 1 is best.
Momentum66/100Medium-term price momentum. Underlying universe rank 35; rank 1 is best.
Growth33/100Revenue and earnings growth. Underlying universe rank 68; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 1.4x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -72.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 92.8% Gross profit retained from each unit of revenue.
- Operating margin
- -83.5% Operating profit retained from revenue.
- Free-cash-flow margin
- -88.8% Free cash flow generated from revenue.
- Return on invested capital
- -74.0% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 6.0% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 2/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningBullish
VNDA shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.44, expected move of 14.0%, and Sharemaestro trend signal inactive.
Conviction42/100
Expected move14.0%
Put/call volume0.44
Insider activity8 / 1
8 acquisitions and 1 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment53/100
Weighted news tone is neutral across 64 relevant articles.
18 positive · 36 neutral · 10 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings05 AugLatest stored earnings date was 05 Aug 2026.
Options expected move14.0%Nearest-chain priced movement where available.
52-week drawdown-49.7%Distance below the 52-week high.
13-week volatility4.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher10 of 2615 weeks finished lower.
Best week+54.7%Week of 27 Feb.
Worst week-19.6%Week of 13 Feb.
Latest week-2.0%Week of 7 Aug.
Shape of recent returns
Strong gains3
Modest gains7
Flat weeks1
Modest losses6
Sharp losses9
Recent vol4.4%13-week weekly-return volatility.
Base vol11.0%52-week weekly-return volatility.
Up/down split26/25Count of positive and negative weeks in the 52-week window.
Average skew7.7% / -6.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average2.6%
Trend breadth54.0%
Trend54.0%active weekly trend signals
MD77.0%positive activity pressure
RS44.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average0.5%
Trend breadth70.0%
Trend70.0%active weekly trend signals
MD64.0%positive activity pressure
RS62.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape34/100
Trend, activity pressure, participation, and risk combine to a 34/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.06; No reversal markers Next-Week ExpectancyPositive 55.10%Next-week expectancy is positive with a 55.10% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors29/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 61; Small Cap Core rank 41 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options47/100VNDA shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.44, expected move of 14.0%, and Sharemaestro trend signal inactive.
Bullish · Call-side pressure · Expected move 14.0% Sentiment53/100Weighted news tone is neutral across 64 relevant articles.
Vanda Pharmaceuticals (VNDA) Stock Holds Steady As Losses Deepen Insiders8 / 18 acquisitions and 1 disposals in the latest 180-day insider tape.
Earnings05 AugLatest stored earnings date was 05 Aug 2026.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 5.00 USD | -2.0% | 6.65 USD | 5.14 USD | -1.25 | -28.59 | 6.7M | Off |
| 31 Jul 2026 | 5.10 USD | -1.5% | 6.73 USD | 5.15 USD | -1.19 | -23.51 | 3.7M | Off |
| 24 Jul 2026 | 5.18 USD | -4.8% | 6.83 USD | 5.15 USD | -1.11 | -21.91 | 4.3M | Off |
| 17 Jul 2026 | 5.44 USD | -12.8% | 6.90 USD | 5.16 USD | -1.11 | -19.44 | 4.9M | Off |
| 10 Jul 2026 | 6.24 USD | 0.5% | 6.94 USD | 5.17 USD | -1.13 | -11.56 | 3.8M | Off |
| 3 Jul 2026 | 6.21 USD | 3.3% | 6.94 USD | 5.16 USD | -1.25 | -10.39 | 3.1M | Off |
| 26 Jun 2026 | 6.01 USD | 3.6% | 6.91 USD | 5.17 USD | -1.34 | -12.57 | 4.4M | Off |
| 19 Jun 2026 | 5.80 USD | -1.2% | 6.89 USD | 5.17 USD | -1.18 | -19.46 | 4.7M | Off |
| 12 Jun 2026 | 5.87 USD | -2.7% | 6.86 USD | 5.17 USD | -1.06 | -16.44 | 4.8M | Off |
| 5 Jun 2026 | 6.03 USD | -6.5% | 6.81 USD | 5.18 USD | -1.02 | -12.26 | 4.1M | Off |
| 29 May 2026 | 6.45 USD | 4.2% | 6.75 USD | 5.18 USD | -0.94 | -10.40 | 4.1M | Off |
| 22 May 2026 | 6.19 USD | -1.4% | 6.68 USD | 5.18 USD | -0.98 | -11.46 | 5.0M | Off |
| 15 May 2026 | 6.28 USD | 0.0% | 6.66 USD | 5.18 USD | -0.96 | -9.07 | 5.6M | Off |
| 8 May 2026 | 6.28 USD | -10.3% | 6.63 USD | 5.18 USD | -0.83 | -9.21 | 8.0M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.